9 results about "Yohimbine" patented technology

The present invention relates to a composition for inhibiting angiogenesis containing yohimbine, and more specifically, to a pharmaceutical preparation and a functional food containing a composition capable of exhibiting preventive, improving, and therapeutic effects on angiogenesis-related diseases such as hemangioma, vascular adhesion, neovascular glaucoma, diabetic retinopathy, macular degeneration, corneal disease caused by neovascularization, or telangiectasia by containing yohimbine capable of inhibiting PDGF-induced vascular smooth muscle cell proliferation and migration through the factor FOXO3a.

Disclosed in the present invention are a yohimbine derivative, and a preparation method therefor and a pharmaceutical composition and use thereof. The structure of the yohimbine derivative is as shown in formula I, and the definition of each substituent in the formula is as described in the description and the claims. The yohimbine derivative of the present invention is used as an α2A-AR antagonist and can be used for treating diseases such as diabetes and diabetic nephropathy.

The invention discloses a yohimbine derivative as well as a preparation method, a pharmaceutical composition and application thereof, the structure of the yohimbine derivative is as shown in formula I. In the formula, the definition of each substituent group is as described in the specification and claims. The yohimbine derivative disclosed by the invention is used as an alpha2A-AR antagonist and can be used for treating diseases such as diabetes mellitus and diabetic nephropathy.

The invention provides a method of promoting weight management in a mammal comprising administering to the mammal a composition comprising at least one weight loss agent and at least one mitochondrial enhancer. The weight loss agent can be selected from the group consisting of psyllium, guar gum, capsaicin, chitosan, caffeine, gamboge, mume, capsaicin, yohimbine, butterfly pea, glucomannan, African mango, guarana, pyruvate, carnitine, beta-glucan, fucoxanthin, raspberry ketone, white kidney bean, kola nut, chromium, ginseng, psyllium, St. John's wort, dandelion, hydroxycitric acid, conjugated linoleic acid, green tea, black tea, coffee bean extract, forskolin, and bitter orange. The mitochondrial enhancer can be selected from the group consisting of beetroot extract, nitrate, idebenone, nicotinamide riboside, elamipretide, vitamin C, vitamin D, vitamin E, thiamine, riboflavin, magnesium, calcium, phosphate, phospholipid, creatine, pyruvate, coenzyme Q10, NADH, niacin, L-carnitine, dichloroacetate, curcumin, schisandrin, and resveratrol. Compositions for weight management are also provided.

The present application provides the use of antagonists of tyramine-ADRA2A signaling axis in the preparation of a medicament for preventing and / or treating inflammatory bowel disease. By using antagonists of tyramine-ADRA2A signaling axis, including but not limited to yohimbine, midaglizole and 2-methoxyimidazolidine, the activation of ADRA2A receptors on intestinal stem cells by tyramine can be inhibited, and the proliferation of intestinal stem cells, the repair of damaged intestines and the relief of intestinal inflammation can be restored. The present application lays a new material foundation for the treatment of inflammatory bowel disease, especially Crohn's disease.

A pharmaceutical composition in the form of droplets for oral administration is disclosed. The pharmaceutical composition is an aqueous solution comprising sodium chloride in an amount of 0.6% to 3% by weight per volume, at least one active ingredient selected from naloxone, yohimbine, albuterol, epinephrine, buprenorphine, and exosomes in an amount of 0.01% to 25% by weight per volume, and having a pH from 3 to 7.5. The composition is converted into droplets with diameters of 0.5 to 5 microns using an atomizer with a vibrating mesh membrane undergoing piezoelectric vibration at a frequency of 25 to 400 kilohertz. The process involves providing the composition in a capsule, inserting the capsule into the atomizer, and activating the atomizer to produce droplets. This system provides precise, efficient, and patient-friendly oral delivery of medications.

The structure of the yohimbine derivative is as shown in Formula I, and the definitions of each substituent in the formula are as described in the specification and claims. The yohimbine derivative can be used as an α2A-AR antagonist to treat diseases such as diabetes.

Yohimbine derivatives, their preparation methods, and uses. This invention discloses compounds of Formula I and pharmaceutical compositions comprising compounds of Formula I. The compounds of Formula I of this invention, as adrenaline receptor α2A (ADRA2A) antagonists or partial antagonists, can treat and / or prevent inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), Crohn's disease (CD), or enteritis.

This invention provides a strain of Akkermansia myxophilus ( Akkermansia muciniphila The present invention provides a probiotic preparation comprising the aforementioned Akkermansia myxophilus or its post-genetically modified organism (PGA). The Akkermansia myxophilus or its post-genetically modified organism (PGA) of the present invention can improve vascular endothelial cell function, increase testosterone secretion, and thus improve erectile dysfunction and reproductive capacity. The probiotic preparation of the present invention may comprise the aforementioned Akkermansia myxophilus or its post-genetically modified organism (PGA) and yohimbine. This preparation can improve erectile dysfunction caused by vascular endothelial dysfunction, improve reproductive function in aged mice, and the components in this preparation have a synergistic effect.